1. Home
  2. TOP vs CGEM Comparison

TOP vs CGEM Comparison

Compare TOP & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TOP Financial Group Limited

TOP

TOP Financial Group Limited

HOLD

Current Price

$16.73

Market Cap

1.3B

Sector

Finance

ML Signal

HOLD

Logo Cullinan Oncology Inc.

CGEM

Cullinan Oncology Inc.

HOLD

Current Price

$21.70

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TOP
CGEM
Founded
2015
2016
Country
Singapore
United States
Employees
N/A
N/A
Industry
Investment Bankers/Brokers/Service
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.4B
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
TOP
CGEM
Price
$16.73
$21.70
Analyst Decision
Strong Buy
Analyst Count
0
8
Target Price
N/A
$30.13
AVG Volume (30 Days)
143.3K
669.2K
Earning Date
01-20-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
81.25
N/A
EPS
N/A
N/A
Revenue
$4,723,765.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$5.20
P/E Ratio
N/A
N/A
Revenue Growth
41.89
N/A
52 Week Low
$0.61
$5.68
52 Week High
$16.35
$23.19

Technical Indicators

Market Signals
Indicator
TOP
CGEM
Relative Strength Index (RSI) 79.37 65.06
Support Level $1.01 $16.40
Resistance Level N/A N/A
Average True Range (ATR) 1.17 1.18
MACD 0.11 0.16
Stochastic Oscillator 92.61 77.80

Price Performance

Historical Comparison
TOP
CGEM

About TOP TOP Financial Group Limited

TOP Financial Group Ltd is operates as an online brokerage firm in Hong Kong specializing in the trading of local and overseas equities, futures, and options products. It conduct the futures and stock brokerage business through three trading platforms, Esunny for futures trading and Longbridge for stock trading, all of which were licensed from third parties and can be easily accessed through its application, or APP, software, and websites. The three platforms are designed for seamless, efficient, and secure trading platform. The company operates and manages its business as a single operating and reportable segment.

About CGEM Cullinan Oncology Inc.

Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.

Share on Social Networks: